Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
Le-Yun Sun, Cheng Chen, Jian-Peng Su, et al.
Bioorganic Chemistry (2021) Vol. 112, pp. 104889-104889
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 138
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 97
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
Xiaojing Pang, Wei Xu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115491-115491
Open Access | Times Cited: 54
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 49
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 44
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 39
Perspectives on SARS-CoV-2 Main Protease Inhibitors
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 23, pp. 16922-16955
Open Access | Times Cited: 90
Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation
Claudio Santi, Cecilia Scimmi, Luca Sancineto
Molecules (2021) Vol. 26, Iss. 14, pp. 4230-4230
Open Access | Times Cited: 87
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Chunlong Ma, Haozhou Tan, Juliana Choza, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1636-1651
Open Access | Times Cited: 69
New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2
Israa A. Seliem, Siva S. Panda, Adel S. Girgis, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105117-105117
Open Access | Times Cited: 64
Advances in the Development of SARS-CoV-2 Mpro Inhibitors
Laura Agost-Beltrán, Sergio de la Hoz‐Rodríguez, Lledó Bou‐Iserte, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2523-2523
Open Access | Times Cited: 50
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic
Ross D. Jansen‐van Vuuren, Luka Jedlovčnik, Janez Košmrlj, et al.
ACS Omega (2022) Vol. 7, Iss. 46, pp. 41840-41858
Open Access | Times Cited: 36
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 21
Selenium compounds as promising antiviral agents
Vimal K. Jain, K. Indira Priyadarsini
New Journal of Chemistry (2024) Vol. 48, Iss. 15, pp. 6534-6552
Closed Access | Times Cited: 6
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 39
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Tika R. Malla, Lennart Brewitz, Dorian-Gabriel Muntean, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7682-7696
Open Access | Times Cited: 31
In silico Studies on the Interaction between Mpro and PLpro From SARS‐CoV‐2 and Ebselen, its Metabolites and Derivatives
Pablo A. Nogara, Folorunsho Bright Omage, Gustavo Roni Bolzan, et al.
Molecular Informatics (2021) Vol. 40, Iss. 8
Open Access | Times Cited: 38
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
Pengxuan Ren, Hui Li, Tianqing Nie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12266-12283
Closed Access | Times Cited: 12
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 11
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus
真 高橋, Ningning Wei, Lin Jin, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105455-105455
Open Access | Times Cited: 28
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS‐CoV‐2 Papain‐Like Protease
Lennart Brewitz, Jos J. A. G. Kamps, Petra Lukacik, et al.
ChemMedChem (2022) Vol. 17, Iss. 9
Open Access | Times Cited: 20
Metal-based strategies for the fight against COVID-19
Hongyan Li, Shuofeng Yuan, Xueying Wei, et al.
Chemical Communications (2022) Vol. 58, Iss. 54, pp. 7466-7482
Closed Access | Times Cited: 19
Enantioselective inhibition of the SARS-CoV-2 main protease with rhenium(i) picolinic acid complexes
Johannes Karges, Miriam A. Giardini, Olivier Blacque, et al.
Chemical Science (2022) Vol. 14, Iss. 3, pp. 711-720
Open Access | Times Cited: 18
Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation
Zhiwei Meng, Shengnan Wang, Fangrong Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 10946-10966
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top